# EU-1-20-1429_public-assessment-report_20200415_20200415_cinacalcet-accordpharma-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
HEALTH
MEDICINES
30 January 2020
EMA/92635/2020
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Cinacalcet Accordpharma
International non-proprietary name: cinacalcet
Procedure No. EMEA/H/C/005236/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential
nature deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
7
1.1. Submission of the dossier
7
1.2. Steps taken for the assessment of the product.
9
2. Scientific discussion
2.1. Introduction.
10
2.1.1. Problem statement
10
2.1.3. The development programme/compliance with CHMP guidance/scientific advice
11
10
2.1.2. About the product.
10
2.2. Quality aspects
11
2.2.1. Introduction
11
2.2.2. Active Substance
11
General Information
11
Manufacture, process controls and characterisation
12
Stability
14
2.2.3. Finished Medicinal Product
14
Description of the product and Pharmaceutical Development
14
Product specification, analytical procedures, batch analysis
17
Adventitious agents
18
2.2.4. Discussion on chemical, and pharmaceutical aspects
18
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
18
2.2.6. Recommendations for future quality development.
18
2.3. Non-clinical aspects
19
2.3.1. Introduction
19
2.3.2. Ecotoxicity/environmental risk assessment
19
2.3.3. Discussion on non-clinical aspects.
19
2.3.4. Conclusion on non-clinical aspects
19
2.4. Clinical aspects
19
2.4.1. Introduction
19
2.4.2. Pharmacokinetics
21
Methods
21
Study design
21
Test and reference products
22
Population(s) studied
22
Analytical methods
24
Pharmacokinetic Variables.
24
Statistical methods
24
Results
25
Safety data
27
2.4.3. Pharmacokinetic Conclusion
28
2.4.4. Pharmacodynamics
28
2.4.5. Post-marketing experience
28
2.4.6. Discussion on clinical aspects
29
Assessment report
EMA/92635/2020
Page 2/33
